Blueprint Genetics

Team

Management team

Tommi is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, San Francisco, and Dubai. He has been running Blueprint Genetics since the beginning and is responsible for sales management, business development and financing. Tommi spends time in Bay Area regularly and is a regular speaker in life science and tech conferences in both US and Europe. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a M.Sc. (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha is the Laboratory Director and Chief Medical Officer of Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has a MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel is the Chief Strategy Officer at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his post-doctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor in patents of DNA sequencing methods.
Tero-Pekka is the Chief Medical Officer, President, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has a MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During this three year postdoctoral training, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.
As Chief Experience Officer, Sofia is responsible for customer experience and marketing at Blueprint Genetics. She leads client services, commercialization of ideas, communication, and marketing. Sofia has an extensive track record in marketing and brand building from consumer goods to life science. She holds a M.Sc. in economics and business administration from HANKEN School of Economics where she studied marketing and law.
As Chief Financial Officer, Riitta Pelli is responsible for Blueprint Genetics’ financial reporting, forecasting as well as strategic, long-term business planning. Riitta has over 15 years' of experience in auditing, financial management and M&A. Prior to joining the Blueprint team she was a partner in the transaction services team at PwC Finland. She holds a M.Sc. from Hanken School of Economics in Helsinki.
Jussi is the head of technology at Blueprint Genetics. He is in charge of directing and developing company's data science, AI and software technology efforts. He has a Master’s Degree in Computer Science and a PhD in Molecular Medicine. He has worked as a visiting scholar and research affiliate at the Broad Institute of MIT and Harvard, and as an Assistant Professor and Manager of Bioinformatics Center at the University of Eastern Finland. Jussi has an extensive track-record of publishing scientific publications, software and databases in the fields of genetics, bioinformatics and data science as well as experience from co-founding two life-science start-ups.
As VPO, Mikko is responsible for operations including safety, quality, delivery and cost of order-to-delivery process globally. He oversees supply chain management and continuous improvement initiatives across the company. He has 20 years of experience in regulated businesses like medical device industry and food industry, and he has extensive experience in various development and leadership positions in health-tech corporations like GE Healthcare and Danaher. He is an expert in developing processes by using continuous improvement methods. Before Blueprint, he was development manager at HUS, the hospital district of Helsinki and Uusimaa in Finland. Mikko has M.Sc. in Industrial Engineering and Management from the Lappeenranta University of Technology.
Meena leads the sales and marketing operations in North America and other regions including Australia and New Zealand. During her years at Blueprint Genetics, she started as the Canadian director of sales and has been a vital part of driving growth in the NA region overall. Meena has a strong desire to build awareness and develop the genetic testing market with a patient-first mindset. Her experience in both industry and clinic have allowed her to develop strengths in sales, business development and strategy, patient counselling, and understanding the genetic diagnostics space. Genetics and genomics have always been a passion, from working on the Wiscott-Aldrich syndrome pathway in fruit flies and Bardet-Biedl syndrome in microscopic worms, obtaining a Master of Science in Human Genetics from Sarah Lawrence College and working as a board certified genetic counsellor, to now helping bring Blueprint Genetics diagnostic innovations to patients and clinicians around the world.
Last modified: 01.30.2020